Clinical trials: Upper Limb
Passive Upper-limb Exoskeleton
Work Physiological-Biomechanical Analysis of a Passive Exoskeleton to Support Occupational Lifting and Flexing Processes
BACKGROUND Industrial tasks that are characterized by high loads, a high repetition rate, and/or awkward body postures, put employees at higher risk to develop work-related musculoskeletal disorders (WRMSD), especially low back…
- Trial name
- ADVANCE (NCT03725982)
- Testing
- Laevo ®, No Laevo ®
- Where
- Germany
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Antiplatelet Aggregation
A Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent Implantation in Non-diabetic Patients
The purpose of the study is to look at the biomarkers of inflammation and platelet activation in patients with drug eluting stents implanted approximately 12 months ago on aspirin and statin, for a 4-week period after the routine…
- Trial name
- DECADES (NCT00493779)
- Testing
- Blood Collection
- Where
- 6 sites in France, Germany and 2 more
- Volunteers
- 103 people
- Sponsor
- Bristol-Myers Squibb
Stroke, Hemiparesis
Upper Extremity Rehabilitation With the BURT Robotic Arm
The overall objective of the proposed study is to carry out usability and design-evaluation assessments of the BURT robotic device for delivering long-term intervention in stroke survivors.
- Trial name
- NCT03965403
- Testing
- Arm motor function retraining with BURT
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Spaulding Rehabilitation Hospital
Symptomatic Cervical Disc Disease
SECURE®-C Cervical Artificial Disc Clinical Study/ SECURE-C Cervical Artificial Disc Postmarket Approval Study
The purpose of the pivotal IDE clinical study was to evaluate the safety and effectiveness of the SECURE®-C Cervical Artificial Disc for the treatment of symptomatic cervical disc disease at one level between C3 and C7, compared…
- Trial name
- NCT00882661
- Testing
- SECURE-C Cervical Artificial Disc, ASSURE Cervical plate and an allograft interbody spacer
- Volunteers
- 380 people
- Sponsor
- Globus Medical Inc
Triple Negative Breast Cancer
A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
The current study is designed to evaluate the efficacy and safety of AL101 monotherapy in subjects with Notch-activated recurrent or metastatic TNBC; Notch activation will be determined by a Next Generation Sequencing (NGS) test.
- Trial name
- TENACITY (NCT04461600)
- Testing
- AL101
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 18 people
- Sponsor
- Ayala Pharmaceuticals, Inc,
Peripheral Arterial Disease
Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME)
The purpose of this study is to evaluate the safety and effectiveness of the Jetstream Atherectomy System for the treatment of Japanese patients with symptomatic occlusive atherosclerotic lesions in native superficial femoral…
- Trial name
- NCT02733653
- Testing
- Jetstream Atherectomy System
- Where
- 10 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Boston Scientific Corporation
Traumatic Amputation of Arm
Interface Kinematics of Transhumeral Prosthetic Sockets Using XROMM
The purpose of this pilot study was to conduct a head-to-head comparison of two designs for transhumeral level upper limb prosthetic sockets: a traditional socket design and a socket design hypothesized to provide greater…
- Trial name
- NCT01546675
- Testing
- Skeletal Stabilization
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- US Department of Veterans Affairs
Renal Cell Carcinoma
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated…
- Trial name
- KEYNOTE-B61 (NCT04704219)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 56 sites in United States, Australia and 12 more
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
Abdominal Surgery, Colon Surgery
D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection
Subjects who are planned to undergo an abdominal (colon) surgery and who will meet the study entry criteria will be randomly divided into 2 groups: for half D-PLEX will be administered concomitantly with the standard of care…
- Conditions
- Abdominal Surgery, Colon Surgery, Post-Op Infection
- Trial name
- NCT03633123
- Testing
- D-PLEX, Standard of Care (SoC)
- Where
- 8 sites in Israel
- Volunteers
- 202 people
- Sponsor
- PolyPid Ltd.
Surgical Site Infection, Colon Surgery
D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)
Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), Compared to a SoC Treated…
- Conditions
- Surgical Site Infection, Colon Surgery, Abdominal Surgery, Post-Op Infection
- Trial name
- D-PLEX312 (NCT04411199)
- Testing
- D-PLEX, Standard of Care (SoC)
- Where
- 58 sites in United States, Bosnia and Herzegovina and 11 more
- Volunteers
- 975 people
- Sponsor
- PolyPid Ltd.
Neuroblastoma
Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma
This clinical trial aims to explore and evaluate the efficacy and safety of combined chemotherapy with arsenic trioxide for stage 4/M neuroblastoma.
- Trial name
- NCT03503864
- Testing
- Arsenic Trioxide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Yang Li
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin
The purpose of this study is to assess the effect of canagliflozin (JNJ-28431754) compared to placebo in the treatment of participants with Type 2 Diabetes Mellitus (T2DM), who have inadequate glycemic control on maximally or…
- Trial name
- NCT02025907
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 57 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Janssen Research & Development, LLC
Risk of Coronary Obstruction Following Transcatheter Aortic Valve Replacement (TAVR) Procedure
The ShortCut™ Study Protocol
A Prospective, Multicenter, Non-Randomized, Single-Arm, Open-Label Clinical Study to Demonstrate the Safety and Effectiveness of the ShortCut™ device for splitting bioprosthetic aortic valve leaflets in patients who are presented…
- Trial name
- NCT04952909
- Testing
- ShortCut™
- Where
- 23 sites in United States, France and 3 more
- Volunteers
- 60 people
- Sponsor
- Pi-cardia
Neoplasms
An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
This single-arm, open-label, multicenter extension study will provide continued bevacizumab therapy to participants with solid tumors who were previously enrolled in a Roche/Genentech sponsored study and who derived benefit from…
- Trial name
- NCT01588184
- Testing
- Bevacizumab
- Where
- 73 sites in Austria, Brazil and 19 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Anemia
A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
This single arm study will evaluate the maintenance of hemoglobin levels, safety and tolerability of once-monthly intravenous administration of Mircera in dialysis patients with chronic renal anemia.
- Trial name
- NCT00737464
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 17 sites in India
- Volunteers
- 132 people
- Sponsor
- Hoffmann-La Roche
Hereditary Angioedema (HAE)
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of icatibant administered to adult Japanese subjects.
- Trial name
- NCT02045264
- Testing
- Icatibant (30 mg)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Shire
Cancer of Head and Neck
Single-arm Phase II Study of NDURE for Patients With HNC
This study will evaluate whether a new patient navigation intervention can decrease delays starting post-operative radiation therapy after surgery for white and African-American head and neck cancer patients.
- Trial name
- NDURE (NCT03821064)
- Testing
- Patient Navigation
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Medical University of South Carolina
Muscular Atrophy, Spinal
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)
This was a phase IV Open-label, single-arm, single-dose, multicenter study, to evaluate the safety, tolerability and efficacy of intravenous administration of OAV101 (AVXS-101) in patients with SMA with bi-allelic mutations in…
- Trial name
- OFELIA (NCT05073133)
- Testing
- OAV101
- Where
- 5 sites in Argentina, Brazil
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Ascites
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
The purpose of this study is to determine whether the investigational drug catumaxomab is a safe and effective treatment for recurrent symptomatic malignant ascites.
- Trial name
- NCT00326885
- Testing
- catumaxomab
- Where
- 18 sites in United States
- Volunteers
- 32 people
- Sponsor
- Neovii Biotech
Acromegaly
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Acromegaly is a chronic disease caused by excessive secretion of growth hormone (GH) and mainly due to benign tumour localized in the pituitary gland.
- Trial name
- PRIMARYS (NCT00690898)
- Testing
- Lanreotide autogel 120 mg
- Where
- 27 sites in Belgium, Czechia and 7 more
- Volunteers
- 108 people
- Sponsor
- Ipsen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.